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Results: There were 153 patients: 45 (29%) EGFR+ and 108 (71%) 
EGFR WT. The median age was 66 years (range, 38-88). The 
population was composed of 38 (25%) Asian ethnicity, 54 (35%) 
never-smokers, and 97 (63%) female sex. The maximal diameter 
of the primary tumour on PET imaging was no different between 
the two EGFR cohorts (mean 4.0 versus 4.0 cm; p = 0.9). The 
SUVmax ranged from 1.1 to 28.9. There was no difference in 
SUVmax between EGFR+ and EGFR WT cohorts (mean 10.4 versus 
10.6; p = 0.9). There was a significant correlation between larger 
tumour size and higher SUVmax (r = 0.47; p < 0.01). Median 
survival was significantly longer for the EGFR+ cohort (28.4 
versus 14.0 months; p = 0.02). On multivariate analysis, when 
accounting for tumour size, SUVmax was not a significant factor 
for survival (p = 0.8). 
Conclusions: In our study there was no correlation between FDG-
PET uptake and EGFR mutation status in patients with metastatic 
NSCLC. The SUVmax cannot be used to predict EGFR mutation 
status or survival. 
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Purpose: Decades of reported experience with low dose rate 
penile brachytherapy have demonstrated local tumour control 
rates and penile preservation of 70-85% at 5-10 years with 
acceptable side effects. Manual source loading is not available in 
most centres in North America so there is a need to explore the 
transition to high-dose rate (HDR) automated afterloading for 
treatment delivery. Dose homogeneity parameters and 
fractionation schemes need to be developed and validated. 
Methods and Materials: Prior experience in interstitial 
template-based penile brachytherapy using either manually 
loaded Ir-192 wire or Pulse Dose Rate after-loading was the basis 
for transitioning to an HDR treatment schema using Varian 
GammaMed. Templates with 15-18 mm spacing designed for LDR 
brachytherapy were found to be not ideal for HDR delivery. 
Spacing was initially 17 mm but was decreased sequentially to 9 
mm. A new design of template was created with holes drilled 
every 3 mm so that inter-plane and inter-needle spacing could 
be generally 9 mm but increased to 12 around the urethra. Four 
patients had a 3-plane implant and two patients had 2 planes. 6-
13 catheters were used. Fractionation was 4200/12 for three 
patients, 4500/12, 5300/17 and 3840/12 for one patient each, 
with fraction sizes of 3.12-3.75 Gy, given bid six hours apart. PTV 
ranged from 4 to 57 cc, median V100: 96% (88-99), V125 75% (40-
98), V150 42% (18-89), V200 16.8% (4.7-32). 
Results: From November 2009 to December 2012 six patients 
with biopsy-proven SCC of the glans penis received HDR 
interstitial brachytherapy. Age range 33-77, Stage T1:2 and T2: 
4, pN0:1, cN0: 5, Grade was MD in five and PD in one. Median 
follow up is 55 months (31-73). All six patients are NED, although 
one patient with local and regional failure was salvaged with 
partial penectomy and left groin dissection. Toxicity was 
considerable. Five patients experienced painful necrosis with 
four requiring Hyperbaric oxygen treatment. One of these 
subsequently had partial penectomy for recurrence; the other 
four eventually healed. Three patients had severe meatal 
stenosis, one requiring a temporary suprapubic tube for 10 
months (now resolved) and one requiring a permanent perineal 
urostomy. Two patients remain potent. Toxicity was related to 
greater needle spacing, larger fraction size, larger PTV volume 
and excessive inhomogeneity. 9-12 mm is now considered ideal 
spacing, with fraction size close to 3 Gy, and with V125 ~ 40%, 
V150~20% and V200 ~5% . The final patient, whose dosimetry 
followed these parameters, was the only one who was 
complication free but also had the smallest PTV. Whether 
following these dosimetric guidelines will permit safe 
implantation of larger volumes remains to be determined. 
Conclusions: HDR penile brachytherapy is effective and can be 
delivered safely (as evidenced by two recent reports from 
Sharma et al. and Kellas-Sleczka et al.) but attention must be 
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Purpose: To estimate the rate of biochemical recurrence in 
prostate cancer treated with intraoperatively planned, low dose 
rate, prostate brachytherapy using an automated delivery system 
(IO-LDRB). 
Methods and Materials: Patients treated with IO-LDRB as a single 
modality treatment for low or low-tier intermediate-risk 
prostate cancer at three Canadian centres between December 
1997 and August 2015 were pooled for analysis. Retrospective or 
prospective databases were maintained at each centre. For this 
analysis the datasets were amalgamated and analyzed using the 
R programming language build 3.1.3 (www.r-project.org). 
Shapiro-Wilks tests of normality, descriptive statistics and 
Kaplan-Meier survival estimates of biochemical relapse-free 
survival (bRFS) were employed for analysis. 
Results: 3286 patients with a median follow up of 44 months (0.0 
- 212.8) and median biochemical follow up of 40.0 months were 
analyzed. Median age for treated patients was 65 (42-84) years. 
In these patients, median initial PSA was 5.6 ng/mL (0.03 – 23.8), 
2390 (74%) were T1 and 862 (26%) were T2, and initial Gleason 
Sum was 6 in 2383 (73%) and 7 in 810 (25%). Most patients had 
low volume disease: median % positive biopsy tissue 5.0% (0.1-
90.0), normal gland volumes: median 34.2cc (10.9 – 77.8) and 
few urinary symptoms: median pre-implant AUA was 5 (0 -33). 
387 (11.8%) of patients received hormones for a median of 3.0 
months (0.5-32.1) prior to implant. Median seed activity was 
0.437 mCi (0.10 – 0.68), D90 was 186.7 Gy (97.0 – 273.0) and V100 
was 99.37% (60.52 – 100.0). In follow up, median last PSA value 
was 0.13 (0.0 – 901.0) and available in 3192 patients. Biochemical 
failure was observed in 139 patients (5.8%) and median time to 
failure was 44.0 months (0.0 – 218.8). Five- and 10-year 
predicted bRFS were 96% and 86%, respectively. Seventy-four 
deaths were observed from all causes and of those, no death was 
attributable to prostate cancer. 
Conclusions: This is the largest cohort of patients treated with 
IO-LDRB and demonstrates it to be an effective treatment option 
for patients with low and low-tier intermediate-risk prostate 
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Purpose: EEC is a rare disease entity with only a handful of 
patients diagnosed every year at most large centres treating 
esophageal cancer. Standard treatments for EEC include 
endoscopic mucosal resection, surgery (S) or chemoradiation 
(CRT). Patients are often not candidate for S or CRT because of 
their comorbidities or for EMR because of extent of tumour. 
Brachytherapy in these instances can give high doses of RT locally 
to the tumour. We present our experience using Radical 
Brachytherapy (RBT) alone in EEC. 
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Methods and Materials: Data of patients with EEC who were 
treated with RBT alone was extracted from a prospective 
database of patients with esophageal cancer treated between 
2008- 15. Demographic, tumour, treatment and outcomes data 
were analyzed. Under direct endoscopic visualization, the 
cranial and caudal extent of the tumour was recorded using 
fluoroscopic imaging. A 4 mm intra-esophageal catheter with a 
marker wire was passed across a guide wire placed under 
endoscopic vision across the tumour into the stomach. Following 
catheter visualization and positioning fluoroscopically, a 
treatment length included the tumour with a 4 cm margin 
craniocaudally. Dose was prescribed at 1 cm from the centre of 
the source axis and was delivered with 192- Ir Varisource HDR 
afterloader. Patients received 24 Gy/4 fractions over two weeks. 
Patients were followed with CT scan and upper GI endoscopy; 
biopsies were taken if there were suspicious findings. Actuarial 
overall (OS), cancer-specific survival (CSS), disease-free survival 
(DFS) were calculated using Kaplan-Meier analyses. 
Results: Twelve patients with EEC treated with RBT alone were 
included in the analysis. Among these patients, 11 patients were 
deemed not candidate for S and/or CRT due to their 
comorbidities and one patient refused S/CRT. Median follow up 
was 11 months (range 3-70 months). Median age was 81 years 
(range 56 - 91 years) and median Charlson-comorbidity index was 
6. They had T1-3N0M0 adenocarcinomas (n = 7), squamous cell 
carcinomas (n = 4) or poorly differentiated carcinoma (n = 1). 
Tumour location included Upper thoracic (n = 2), lower thoracic 
(n = 5) and GEJ (n = 5). Median treatment length was 13 cm 
(range 8 - 17 cm). Two patients had local recurrence and died 
from their cancer; three patients died from non-cancer-related 
causes. No significant acute toxicities (e.g. perforations, severe 
esophagitis, bleeding) were recorded. Both the three- and five-
year OS were 50%: three- and five-year CSS 76%: both three- and 
five-year DFS = 76%. Long-term complications included 
esophageal strictures (n = 3; median time to stricture 4.8 (3.5 - 
16 months) that needed dilations and chronic esophageal ulcer 
that healed after 14 months (n = 1). No patient developed a 
fistula. 
Conclusions: In this series of patients unsuited for S, CRT or EMR 
due to comorbidities/ tumour extension/ patient refusal to S or 
CRT, RBT alone was a safe and effective treatment modality for 
EEC. This is one of the largest North American series of EEC 
treated with RBT alone. 
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Purpose: The present study aimed to perform a direct 
comparison of several existing risk stratification tools for 
localized prostate cancer in two large databases using a variety 
of statistical techniques to quantify their ability to predict for 
biochemical failure. 
Methods and Materials: Patients who were treated with external 
beam radiotherapy (EBRT) or brachytherapy for localized 
prostate cancer were selected from a multicentre database (n = 
7974) and a validation database (n = 2266). The primary outcome 
was biochemical failure-free survival (BFFS) using the ASTRO 
“Phoenix” definition. Net reclassification index (NRI), 
concordance index (C-index) and decision curve analysis (DCA) 
were used to predict BFFS and overall survival. 
Results: NRI and C-index identified the Prostate Cancer Risk 
Stratification (ProCaRS) , Cancer of the Prostate Risk Assessment 
(CAPRA) 10-point and 3-point as superior to the Genitourinary 
Radiation Oncologists of Canada (GUROC) and National 
Comprehensive Cancer Network (NCCN) risk stratification 
systems. C-indices for CAPRA (10-point), CAPRA (3 category) and 
ProCaRS were 0.72, 0.70 and 0.71 for multicentre database and 
0.66, 0.64, 0.63 for the validation database respectively. 
However, many of these comparisons were not found to be 
significant. DCA identified minimal differences across the 
different risk stratification systems with no system emerging 
with optimal net benefit. 
Conclusions: A direct comparison between existing risk 
stratification tools, using a variety of statistical techniques, 
demonstrated minimal clinically significant differences in 
discriminative ability between the various tools with the CAPRA 
and ProCaRS systems performing best. This study highlights the 
limitations of current risk stratification tools. The incorporation 
of novel prognostic variables such as genomic markers is needed 
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Purpose: Patient reported outcomes (PROs) can enhance person-
centred care. Clinical use of the Edmonton Symptom Assessment 
Scale (ESAS-R) is a standard of care in Ontario cancer centres, 
but evidence from clinician surveys illustrates that ESAS-R has 
limited value in men with localized prostate cancer as it does not 
address symptoms most relevant to the prostate cancer patient 
population. The Expanded Prostate Cancer Index Composite for 
Clinical Practice (EPIC-CP) has been validated as a PRO designed 
for use in enhancing the patient encounter in the care of men 
with prostate cancer. We undertook a systematic evaluation of 
EPIC-CP (used in addition to ESAS-R) in four Ontario cancer 
centres.  
Methods and Materials: Prostate cancer patients were recruited 
from four centres over eight months (to June 2015). Eligible 
patients were those attending radiation or surgical consultation, 
follow up, or on-treatment review clinics. Consenting patients 
completed the EPIC-CP tool on a tablet. The resultant scores 
were graphically summarized and made available to the 
nurse/physician at the clinical encounter. Evaluations of EPIC-CP 
from the patients’ perspectives were obtained quantitatively by 
use of a nine-item questionnaire completed by each patient post-
encounter. Providers’ perspectives were obtained through 
thematic content analysis of one-on-one semi-structured 
interviews with participating clinicians. 
Results: Overall, 287 Patients completed an average of 3 EPIC-
CP measures during the study (range 1-11). Over 90% of patients 
completed all items at each encounter; missing items (skipped 
by the patient) ranged from 0.5% (bowel function) to 9.5% (sexual 
function). Only eight patients (2.8%) felt that EPIC-CP did not 
enhance communication, and only 15 (5%) felt that the sexual 
function questions were not important to include. Thematic 
analysis of clinicians’ perspectives revealed that EPIC-CP 
captured essential prostate-specific effects, enhanced person-
centred communication, and facilitated customization of 
interventions thus enhancing person-centred care. EPIC-CP and 
ESAS-R showed comparable sensitivity in detecting vitality and 
depression issues in this patient population. 
